Bayer AG annual operating cash flow
2021
2022
2023
2024
2025
Bayer AG Operating Cash Flow Growth & History (BAYN)
Bayer AG's operating cash flow was €5.93B for fiscal 2025.
View full Bayer AG company overviewBayer AG annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €5.93B | −€1.44B | −19.52% |
| 2024 | 2024-12-31 | €7.37B | €2.25B | +43.99% |
| 2023 | 2023-12-31 | €5.12B | −€1.98B | −27.86% |
| 2022 | 2022-12-31 | €7.09B | €2.00B | +39.38% |
| 2021 | 2021-12-31 | €5.09B | — | — |
Bayer AG quarterly operating cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €690.0M | −€368.0M | −34.78% |
| Q1 2026 | 2026-03-31 | −€1.79B | — | — |
| Q4 2025 | 2025-12-31 | €4.20B | — | — |
| Q3 2025 | 2025-09-30 | €1.69B | — | — |
| Q2 2025 | 2025-06-30 | €1.06B | — | — |
Bayer AG operating cash flow trends
Between the periods ended 2021-12-31 and 2025-12-31, Bayer AG's operating cash flow increased from €5.09B to €5.93B, a change of €841.0M. The latest reported quarter, Q2 2026, shows €690.0M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company official filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
